Kennedy, SH, Dickens, SE, Eisfeld, BS, etal. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999; 56(2–3): 201–208.
Williams, K, Reynolds, MF. Sexual dysfunction in major depression. CNS Spectr. 2006; 11(8 suppl 9): 19–23.
Clayton, A, Keller, A, McGarvey, EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006; 91(1): 27–32.
Ashton, AK, Jamerson, BD, Weinstein, WL, etal. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Current Therapeutic Research. 2005; 66(2): 96–106.
Montejo, AL, Llorca, G, Izquierdo, JA, etal. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62(suppl 3): 10–21.
Clayton, A, Kornstein, S, Prakash, A, etal. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007; 4(4 Pt 1): 917–929.
Clayton, AH, Pradko, JF, Croft, HA, etal. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357–366.
Weisler, R, Joyce, M, McGill, L, etal. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009; 14(6): 299–313.
Cutler, AJ, Montgomery, SA, Feifel, D, etal. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009; 70(4): 526–539.
Bortnick, B, El-Khalili, N, Banov, M, etal. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011; 128(1–2): 83–94.
Earley, W, McIntyre, A, Wang, G, etal. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) [Abstract]. Int J Psychiatry Clin Pract. 2008; 12: 332.
El-Khalili, N, Joyce, M, Atkinson, S, etal. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010; 13(7): 917–932.
Bauer, M, Pretorius, HW, Constant, EL, etal. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009; 70(4): 540–549.
Katila, H, Mezhebovsky, I, Mulroy, A, etal. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013; 21(8): 1769–1784.
Liebowitz, M, Lam, RW, Lepola, U, etal. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010; 27(10): 964–976.
Hu, XH, Bull, SA, Hunkeler, EM, etal. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004; 65(7): 959–965.
Williams, VS, Baldwin, DS, Hogue, SL, etal. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry. 2006; 67(2): 204–210.
Sheehan, DV, Lecrubier, Y, Sheehan, KH, etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20): 22–33.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56–62.
Keller, A, McGarvey, EL, Clayton, AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther. 2006; 32(1): 43–52.
Kennedy, SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008; 10(3): 271–277.
Zimmerman, M, Posternak, M, Friedman, M, etal. Which factors influence psychiatrists’ selection of antidepressants?
Am J Psychiatry. 2004; 161(7): 1285–1289.
Montejo-Gonzalez, AL, Llorca, G, Izquierdo, JA, etal. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997; 23(3): 176–194.
Maguire, GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002; 63(suppl 4): 56–62.
Kelly, DL, Conley, RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006; 31(3): 340–346.
Fava, M, Dording, CM, Baker, RA, etal. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord. 2011; 13(1). DOI: 10.4088/PCC.10m00994gre.
Montejo, AL, Perahia, DG, Spann, ME, etal. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med. 2011; 8(3): 773–782.
Kennedy, SH, Eisfeld, BS, Dickens, SE, etal. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000; 61(4): 276–281.
Nurnberg, HG. Managing treatment-emergent sexual dysfunction associated with serotonergic antidepressants: before and after sildenafil. J Psychiatr Pract. 2001; 7: 92–108.
Segraves, RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry. 1998; 59(suppl 4): 48–54.
Clayton, AH, Croft, HA, Horrigan, JP, etal. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67(5): 736–746.
Perlis, RH, Laje, G, Smoller, JW, etal. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009; 34(7): 1819–1828.
Bishop, JR, Moline, J, Ellingrod, VL, etal. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825 T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006; 31(10): 2281–2288.
Cipriani, A, Furukawa, TA, Salanti, G, etal. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746–758.